LPTI Longport Inc (CE)

Longport, Inc. (OTC PK: LPTI), a medical technology specialist in high-frequency high resolution ultrasound imaging, today announced that its UK subsidiary, Longport International, is participating in a $2 million project to develop a high resolution phased array ultrasound imaging system. This project is partly supported by a grant from the UK�s Department of Trade & Industry. The system under development will be capable of imaging at center frequencies greater than 25 MHz as well as at lower frequencies and is expected to exceed the imaging resolution of all current commercial multi-element ultrasound systems. The project, which is led by Longport International, involves the University of Manchester, Phoenix Inspection, and Newbury Electronics, all from the UK. Importantly, the system under development will combine very high performance with affordability through the utilization of novel transducer and system designs and the development of specialist integrated circuits. Initial applications for this system are expected to be cancer imaging, including the mapping of skin cancers, wound assessment and prevention and superficial musculoskeletal imaging as well as specialist engineering inspections. Welcoming the new partnership, the UK�s Science and Innovation Minister, Lord Sainsbury, said, �This initiative provides a real opportunity to harness the world class expertise that we possess in the UK and direct it towards the task of wealth creation. By providing a focus for collaboration and delivery, this partnership should establish British industry as the world leader in this area and be an attractive proposition for investors.� Paul Wilson, Managing Director of Longport International, said, �This project will build on expertise developed by Longport and the University of Manchester in high resolution ultrasound imaging and is seen as a logical evolution of Longport�s established medical imaging technology. The development is expected to bring the benefits of faster imaging as well as a broader range of image enhancement and processing techniques, including Doppler imaging, to Longport�s current customer groupings as well as expanding the markets that Longport can address.� About Longport, Inc. Longport, Inc. of Glen Mills, Pennsylvania, is a medical technology company that specializes in high resolution ultrasound imaging. After several years and a multi-million dollar investment in the technology, Longport has secured patents, copyrights and FDA permission to market. The Company�s technology has been used to engineer a unique high resolution ultrasound imaging system. For further information please contact Longport, Inc. at 1-800-289-6863 or visit our website at www.longportinc.com. Forward-looking Information and the Private Securities Litigation Reform Act of 1995 Certain statements in this press release, including statements concerning product development milestones and anticipated events, are �forward-looking statements� within the Private Litigation Reform Act of 1995. Forward Looking Statements are based on the opinions and estimates of management at the time the statements are made and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. The words �believe,� �expect,� �intend,� �anticipate,� variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could affect Longport�s actual results include, among others, uncertainties as to the Company�s ability to manage potential problems, delays or anticipated expenses, including problems, delays or expenses involving manufacturing. Readers are cautioned not to place undue reliance upon these forward-looking statements that speak only to the date of this release. Reference is made to Longport�s 2004 annual report on Form 10-K filed with the Securities and Exchange Commission for a more definitive description of such factors. Longport, Inc. undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events. Longport, Inc. (OTC PK: LPTI), a medical technology specialist in high-frequency high resolution ultrasound imaging, today announced that its UK subsidiary, Longport International, is participating in a $2 million project to develop a high resolution phased array ultrasound imaging system. This project is partly supported by a grant from the UK's Department of Trade & Industry. The system under development will be capable of imaging at center frequencies greater than 25 MHz as well as at lower frequencies and is expected to exceed the imaging resolution of all current commercial multi-element ultrasound systems. The project, which is led by Longport International, involves the University of Manchester, Phoenix Inspection, and Newbury Electronics, all from the UK. Importantly, the system under development will combine very high performance with affordability through the utilization of novel transducer and system designs and the development of specialist integrated circuits. Initial applications for this system are expected to be cancer imaging, including the mapping of skin cancers, wound assessment and prevention and superficial musculoskeletal imaging as well as specialist engineering inspections. Welcoming the new partnership, the UK's Science and Innovation Minister, Lord Sainsbury, said, "This initiative provides a real opportunity to harness the world class expertise that we possess in the UK and direct it towards the task of wealth creation. By providing a focus for collaboration and delivery, this partnership should establish British industry as the world leader in this area and be an attractive proposition for investors." Paul Wilson, Managing Director of Longport International, said, "This project will build on expertise developed by Longport and the University of Manchester in high resolution ultrasound imaging and is seen as a logical evolution of Longport's established medical imaging technology. The development is expected to bring the benefits of faster imaging as well as a broader range of image enhancement and processing techniques, including Doppler imaging, to Longport's current customer groupings as well as expanding the markets that Longport can address." About Longport, Inc. Longport, Inc. of Glen Mills, Pennsylvania, is a medical technology company that specializes in high resolution ultrasound imaging. After several years and a multi-million dollar investment in the technology, Longport has secured patents, copyrights and FDA permission to market. The Company's technology has been used to engineer a unique high resolution ultrasound imaging system. For further information please contact Longport, Inc. at 1-800-289-6863 or visit our website at www.longportinc.com. Forward-looking Information and the Private Securities Litigation Reform Act of 1995 Certain statements in this press release, including statements concerning product development milestones and anticipated events, are "forward-looking statements" within the Private Litigation Reform Act of 1995. Forward Looking Statements are based on the opinions and estimates of management at the time the statements are made and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could affect Longport's actual results include, among others, uncertainties as to the Company's ability to manage potential problems, delays or anticipated expenses, including problems, delays or expenses involving manufacturing. Readers are cautioned not to place undue reliance upon these forward-looking statements that speak only to the date of this release. Reference is made to Longport's 2004 annual report on Form 10-K filed with the Securities and Exchange Commission for a more definitive description of such factors. Longport, Inc. undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.